Literature DB >> 1900518

Cholinergic response of isolated rat atria to recombinant rat interferon-gamma.

E Borda1, C P Leirós, L Sterin-Borda, M M de Bracco.   

Abstract

Addition of recombinant rat interferon-gamma (IFN-gamma) to beating rat atria decreased the contractile strength in a dose-dependent manner. The effect was specific of IFN-gamma since it was abrogated by monoclonal anti-rat IFN-gamma. It required the activation of the cholinergic system of the heart as inhibition of both nicotinic (10(-7) M hexametonium) and muscarinic cholinoceptors (10(-7) M atropine) prevented the reaction. Hemicholinium (2 x 10(-5) M) and tetrodotoxin (5 x 10(-7) M) also reduced the response. Likewise, IFN-gamma potentiated the action of the muscarinic agonist carbachol. IFN-gamma simulated the biological effect of cholinergic agonists because: (a) it increased cGMP formation; (b) it decreased cAMP formation; and (c) it reduced heart contractility at doses that can be considered physiologic. IFN-gamma also modified the muscarinic receptor by interfering with the binding of the radiolabelled antagonist quinuclidinyl benzilate [( 3H]QNB). It is suggested that IFN-gamma binding to IFN-gamma receptors in the heart may lead to a cholinergic response by interaction of both receptor systems on the surface of atrial cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1900518     DOI: 10.1016/0165-5728(91)90071-e

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  3 in total

Review 1.  Could interferon-gamma be a therapeutic target for treating heart failure?

Authors:  Scott P Levick; Paul H Goldspink
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

2.  Biochemical markers of cardiac dysfunction in children with obstructive sleep apnoea (OSA).

Authors:  Daniel Hirsch; Carla A Evans; Melanie Wong; Rita Machaalani; Karen A Waters
Journal:  Sleep Breath       Date:  2018-05-09       Impact factor: 2.816

3.  Benzonidazole therapy modulates interferon-γ and M2 muscarinic receptor autoantibody responses in Trypanosoma cruzi-infected children.

Authors:  Romina A Cutrullis; Guillermo F Moscatelli; Samanta Moroni; Bibiana J Volta; Rita L Cardoni; Jaime M Altcheh; Ricardo S Corral; Héctor L Freilij; Patricia B Petray
Journal:  PLoS One       Date:  2011-10-31       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.